Europe — EMA
Opdualag (Nivolumab, Relatlimab)
Nivolumab, the active ingredient in Opdualag, is a immune checkpoint inhibitor presented as a sterile powder for intravenous infusion use. It treats certain advanced cancers in adult patients.
Request sourcing
1
Pack/s
What is Nivolumab, Relatlimab?
Nivolumab, the active ingredient in Opdualag, is a immune checkpoint inhibitor presented as a sterile powder for intravenous infusion use. It treats certain advanced cancers in adult patients. GNH USA supplies Opdualag as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.
GNH USA supplies Opdualag as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.
What is Nivolumab, Relatlimab used for?
Opdualag combines the N ‑ ...
What are the side effects of Nivolumab, Relatlimab?
Common
What precautions apply to Nivolumab, Relatlimab?
The
Product details
Drug
Nivolumab, Relatlimab
Route
Intravenous Use
Manufacturer
Bristol-Myers Squibb Pharma Eeig
Origin
EU
